Regulation of pinocytosis in murine macrophages by colony-stimulating factors and other agents.
Lucifer yellow (LY) accumulation was used to measure macrophage pinocytosis. The hematopoietic growth factors, macrophage colony-stimulating factor (CSF-1), granulocyte-macrophage CSF (GM-CSF), and interleukin 3, and the macrophage activators, lipopolysaccharide and zymosan, all stimulated LY uptake in both murine bone marrow-derived macrophages (BMMs) and resident peritoneal macrophages (RPMs) without affecting LY efflux. The stimulation of pinocytosis in the poorly cycling RPMs and in BMMs by nonmitogens dissociates stimulation of pinocytosis from subsequent DNA synthesis. Regulation of pinocytosis in BMMs appears to be independent of that of urokinase-type plasminogen activator expression. The increases in CSF-mediated BMM pinocytosis were not inhibited by pertussis toxin, by elevations in intracellular cAMP, or by glucocorticoids and were only partially inhibited by inhibitors of Na+/H+ antiport and Na+/K(+)-ATPase activities. Protein kinase C activation could be involved in regulating BMM pinocytosis because phorbol myristate acetate, oleoylacyglycerol, and exogenously added phospholipase C can all stimulate it. Ca2+ ionophores were inactive, whereas the Na+/H+ ionophore monensin potently inhibited BMM pinocytosis.
Knight
K R
KR
University of Melbourne, Department of Medicine, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Vairo
G
G
Hamilton
J A
JA
D000818:Animals; D001854:Bone Marrow Cells; D002118:Calcium / Q000378:metabolism; D003115:Colony-Stimulating Factors / Q000494:pharmacology*; D000242:Cyclic AMP / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D007377:Interleukin-3 / Q000494:pharmacology; D007546:Isoquinolines / Q000378:metabolism; D016173:Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects*; D051379:Mice; D008815:Mice, Inbred Strains; D008985:Monensin / Q000494:pharmacology; D010529:Peritoneal Cavity / Q000166:cytology; D037342:Pertussis Toxin; D010873:Pinocytosis / Q000187:drug effects*; D011493:Protein Kinase C / Q000502:physiology; D012964:Sodium / Q000378:metabolism; D010738:Type C Phospholipases / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D003115:Colony-Stimulating Factors; D007377:Interleukin-3; D007546:Isoquinolines; D010566:Virulence Factors, Bordetella; D003907:Dexamethasone; D016173:Macrophage Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D008985:Monensin; C017475:lucifer yellow; D012964:Sodium; D000242:Cyclic AMP; D037342:Pertussis Toxin; D011493:Protein Kinase C; D010738:Type C Phospholipases; D014568:Urokinase-Type Plasminogen Activator; D002118:Calcium